

Biomnis



Ovarian cancer

HE4 & ROMA score



Biomnis

Ovarian cancer in the world*

Accounting for around 4% of all cancers diagnosed in women

The estimated World age-standardised incidence rate for the more developed regions of the world was **9 per 100,000** and 5 per 100,000 for the less developed countries.

225,000 new cases

Incidence rates vary considerably across the world, with World age-standardised rates in more developed countries being **nearly twice as high as** those in less developed countries

Numerous women are involved in a suspected case of ovarian cancer.

The symptoms are non-specific and are of late-onset in this type of cancer.



- Establish an early diagnosis
- Detect relapse

Provide multidisciplinary and rapid care



The diagnosis

The diagnosis relies on the medical background, the clinical examination and medical imaging (ultrasound and MRI).

The definitive diagnosis of cancer is made through anatomical pathology investigations and requires a histology sample to be taken.

When confronted with a diagnosis of epithelial ovarian cancer, screening for the BRCA1 or 2 mutation is strongly advised*.

Medical background

Screening for risk factors, notably a personal and familial history of cancer and comorbidities.

Risk increases

- Age
- Caucasian population
- Late menopause
- BRCA gene mutations: BRCA1 (risk increases by 60-fold), BRCA2 (30-fold)
- Nulliparity, infertility, endometriosis

Risk decreases

- History of hysterectomy
- Oral contraception
- Multiparity

Clinical and complementary investigations



The initial pre-treatment dose for the CA125 marker is recommended.

The assays for markers CA 19-9 and CAE are only performed if clinically or radiologically indicative of an ovarian mucinous tumour or suggestive of a differential diagnosis of a digestive tumour.

The prognosis

It is essential to determine the disease stage at the time of diagnosis.



Survival at 5 years of ovarian cancer

Other factors influencing the prognosis

age, comorbidities, histology results, the grade and presence of a residual tumour following surgery.

Relapses

The risk of a relapse at 5 years is 80%.

The majority of relapses appear in the first three years of treatment.

Early onset relapses have a poor prognosis.

Early diagnosis and the detection of relapses is the only way to improve the short-term prognosis.

HE4: Human Epididymis-specific protein 4

HE4 is an epididymis protein known since 1991. Since 1999, over expression was identified in patients suffering from first stages of ovarian cancer (stages I and II) and mainly found in cases of serous cancers. Its expression is independent of CA125 and it is effective in 50% of cancers which do not express CA125.

The HE4 protein offers better sensitivity and specificity than CA125.

Its combination with serum markers improves the sensitivity and specificity of ovarian cancer detection in the early stages as well as in cases of relapse.



HE4 is more specific than CA125 and permits the differential diagnosis of endometriosis to be made.



The HE4 protein marker is not totally specific to ovarian tissue, or ovarian cancer: it is over-expressed in thyroid cancers, pulmonary adenocarcinomas, mammary adenocarcinomas and mesotheliomas.

ROMA: Risk of Ovarian Malignancy Algorithm

The ROMA algorithm assesses the risk of malignancy by combining the serum HE4 result, the CA125 result and the menopausal status.

It allows patients to be classed according to their risk of malignancy level, i.e. low or high.

Interpretation*

In pre-menopausal women:

- ROMA ≥ 11.4 = high risk of ovarian cancer
- ROMA < 11.4 = low risk of ovarian cancer

In post-menopausal women:

- ROMA ≥ 29.9 = high risk of ovarian cancer
- ROMA < 29.9 = low risk of ovarian cancer

In a multicentric study that included 457 women presenting with a pelvic mass, the ROMA algorithm allowed an ovarian epithelial cancer to be distinguished from a benign tumour in 94.3% of patients, and notably to identify 85.3% of stage I and stage II cases**.

*Method used ECL Roche: the ROMA risk can only be calculated by combining CA125 and HE4 in the same technological method.

**Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs. the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010;203:208.e1-6.

Clinical interest of the HE4 marker and ROMA

Assistance in the early diagnosis of epithelial ovarian cancer (stages I and II) and the detection of relapses

- The implementation of treatment as quickly as possible and at an early stage
- Increased survival rate

Better risk staging in patients with a pelvic mass or an ovarian cyst

- Exclusion of a malignant tumour or rapid orientation towards a multidisciplinary and specialised team
- Reduction of unnecessary surgical interventions



Test request

HE4* + CA125 *+ score ROMA

The ROMA malignancy risk calculation integrates the HE4 result, CA125 result and the menopausal status of the patient.

Please indicate: whether the patient is **pre-menopausal or menopausal.**

*HE4 and CA125 are measured using the same technology, which does not authorise the integration of a transferred CA125 result

Sample

- 1mL of serum
- Minimum quantity: 600 μL
- The serum must be separated from the blood cells then frozen at -20°C.

To find out more about this subject

Find all the necessary details at:

- www.biomnis.com > Test guide
- Biomnis code: HE4
- Biomnis code: CA125

Contact

Laurence STROMPF-SILVESTRE Tél. : 01 49 59 63 14 laurence.strompf-silvestre@biomnis.com

References

Li et al. Does risk ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: A meta-analysis BMC Cancer 2012;12:258

Urban et al. Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk of ovarian cancer Cancer Epidemiol Biomarkers Prev.2012; 21(11):2087-2094

T Van Gorp et al. HE4 and CA125 as a diagnostic test in ovarian cancer : prospective validation of the Risk of Ovarian Malignancy Algorithm Br. J Cancer 2011;104:863-870 HAS/INC Guide-Affection longue durée-Tumeur maligne, affection maligne du tissu lymphatique ou hématopoiétique Cancer de l'ovaire, janvier 2010 www.has-sante.fr et sur www.e-cancer.fr

Lamy P. HE4, un nouveau marqueur des cancers épithéliaux ovariens : évaluation des performances analytiques Ann Biol Clin 2010;68(3):325-9

Moore RG et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass American Journal of Obstetrics & gynecology 2010;203(3):228

Huhtinen et al. Serum HE4 concentration differentiates malignant ovarian endometriotic cysts Br. J Cancer, 2009; 100(8);1315-1319

Moore RG et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecologic Oncology 2009;112(1): 40–46

Moore RG et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus Gynecologic Oncology 2008;110: 196–201

Moore RG et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecologic Oncology 2008;108: 402–408





Biomnis

Eurofins Biomnis International Division 17/19 avenue Tony Garnier BP 7322 - 69357 LYON Cedex 07 - FRANCE E-mail : international@biomnis.com www.biomnis.com